The TGFβ (transforming growth factor β) superfamily proteins are pleiotropic cytokines that regulate a diverse range of cellular processes, including proliferation, differentiation, migration, adhesion and death.  The TGFβ superfamily elicits 4 signaling pathways: TGFβ, Bone Morphogenic Protein (BMP), Activin, and Nodal.  Each pathway signals through a heteromeric receptor complex composed of at least two type-I and two type-II transmembrane receptors containing cytoplasmic serine/threonine kinase domains. These receptors are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found only in the type I receptors. Either type receptor may initially bind ligand, followed by the recruitment of an alternate-type receptor counterpart to form a signal-activating complex. TGFBR2 (transforming growth factor β receptor 2), also known as TGFR-2 and TGFβ-RII, is a type II receptor for TGFβ that functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. TGFBR2 binds TGFβ1, TGFβ3, and TGFβ5 with high affinity, and TGFβ2 with two orders of magnitude lower affinity. TGFBR2 regulates a plethora of physiological and pathological processes, including wound healing, extracellular matrix production, immunosuppression, and tumorigenesis. Mutations in the TGFBR2 gene are associated with Marfan syndrome (MFS), Loeys-Deitz Aortic Aneurysm Syndrome (LDS), thoracic aortic aneurysms and dissection (TAAD), thoracic aortic aneurysms type 3 (AAT3) and cancers, such as hereditary non-polyposis colorectal cancer 6 (HNPCC6) and esophageal cancer (ESCR).

The TGFβ (transforming growth factor β) superfamily proteins are pleiotropic cytokines that regulate a diverse range of cellular processes, including proliferation, differentiation, migration, adhesion and death.  The TGFβ superfamily elicits 4 signaling pathways: TGFβ, Bone Morphogenic Protein (BMP), Activin, and Nodal.  Each pathway signals through a heteromeric receptor complex composed of at least two type-I and two type-II transmembrane receptors containing cytoplasmic serine/threonine kinase domains. These receptors are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found only in the type I receptors. Either type receptor may initially bind ligand, followed by the recruitment of an alternate-type receptor counterpart to form a signal-activating complex. TGFBR2 (transforming growth factor β receptor 2), also known as TGFR-2 and TGFβ-RII, is a type II receptor for TGFβ that functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. TGFBR2 binds TGFβ1, TGFβ3, and TGFβ5 with high affinity, and TGFβ2 with two orders of magnitude lower affinity. TGFBR2 regulates a plethora of physiological and pathological processes, including wound healing, extracellular matrix production, immunosuppression, and tumorigenesis. Mutations in the TGFBR2 gene are associated with Marfan syndrome (MFS), Loeys-Deitz Aortic Aneurysm Syndrome (LDS), thoracic aortic aneurysms and dissection (TAAD), thoracic aortic aneurysms type 3 (AAT3) and cancers, such as hereditary non-polyposis colorectal cancer 6 (HNPCC6) and esophageal cancer (ESCR).

 

Product Details

 

Gene Symbol: TGFBR2; AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFBRII; TGFbeta-RII

 

NCBI Gene ID: 7048

 

Uniprot Entry: P37173

 

Construct Details: The recombinant human TGFBR2-Fc fusion protein is expressed as a 365 amino acid protein consisting of Thr23 - Asp159 region of TGFBR2 (UniProt accession #P37173) and a C-terminal Fc fusion from human IgG1, which exists as a dimer under non-reducing condition (see the gel image above, labeled as "DTT: -").

 

Source: Human cells stably expressing human TGFBR2-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence:

TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEK

PQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMC

SCSSDECNDNIIFSEEYNTSNPDSSGTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI

SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH

QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSPGK

 

M.W.: Calculated molecular mass (kDa): 41.1; Estimated by SDS-PAGE under reducing condition (kDa): ~60

 

Calculated PI: 5.84

 

Calculated extinction coefficients (M-1 cm-1, at 280nm):  45015

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Immobilized TGFBR2 protein binds human TGFβ1 in a functional ELISA.  Blocks TGFβ1-mediated signaling activity.

 

 

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Cell 68:775-785(1992)

2. Nat. Genet. 19:17(1998)

3. Cancer Res. 61:482(2001)

4. Nat. Genet. 36:855(2004) 

5. Nat. Genet. 37:275(2005)

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0176-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.